Guardant Health Launches Enhanced Guardant360 Test On Guardant Infinity Platform; New Test Covers 10 Times More Genes And Quantifies Tumor Burden With 10 Times Higher Sensitivity; Medicare And Major Private Payers Cover Test For Comprehensive Genomic Profiling Of Advanced Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Guardant Health has launched an enhanced version of its Guardant360 test on the Guardant Infinity platform. The new test covers 10 times more genes and quantifies tumor burden with 10 times higher sensitivity. Medicare and major private payers cover the test for comprehensive genomic profiling of advanced solid tumors.
July 23, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health has introduced an improved Guardant360 test on its Guardant Infinity platform, significantly enhancing gene coverage and sensitivity. The test is covered by Medicare and major private payers for advanced solid tumors.
The launch of the enhanced Guardant360 test is a significant development for Guardant Health. The increased gene coverage and sensitivity improve the test's utility, potentially driving higher adoption rates. Coverage by Medicare and major private payers further supports its market penetration, likely leading to positive short-term stock price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100